Developing a vaccine to prevent human ehrlichiosis caused by ticks
Targeted Prevention of Human Ehrlichiosis
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-10883656
This study is working on a vaccine to help protect people from a serious tick-borne illness caused by a germ called Ehrlichia chaffeensis, aiming to boost the body's defenses so we can prevent this dangerous infection before it starts.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-10883656 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a vaccine to protect against human monocytic ehrlichiosis, a serious tick-borne disease caused by the bacterium Ehrlichia chaffeensis. The approach involves identifying and targeting specific proteins on the surface of the bacterium that are crucial for its survival and entry into human cells. By immunizing animal models with these proteins, the researchers aim to generate a strong immune response that could lead to effective protection in humans. The ultimate goal is to provide a preventive measure against this life-threatening infection, especially since current treatments are only effective if administered early.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of tick exposure, particularly those living in endemic areas or involved in outdoor activities.
Not a fit: Patients who have already contracted ehrlichiosis or those with contraindications to vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a vaccine that significantly reduces the incidence of human ehrlichiosis.
How similar studies have performed: While there is ongoing research into tick-borne diseases, this specific approach to vaccine development targeting Ehrlichia chaffeensis is novel and has not been extensively tested.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RIKIHISA, YASUKO — OHIO STATE UNIVERSITY
- Study coordinator: RIKIHISA, YASUKO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.